Condition: Malignant Neoplasm of Brain · Sponsor: Novelwise Pharmaceutical Corporation
This clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long-term safety and efficacy of NBM-BMX administered in combination with TMZ.
This description comes directly from the study's public registry record.
Chia-Chung Hou, Ph.D. · 886 2 26559109 · alison.hou@novelwisepharma.com
Cherry Hsu · 886 2 27891060 · cherry.hsu@effpha.com
Always discuss trial participation with your own doctor first.
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Not Yet Recruiting |
| Linkou Chang-Gung Memorial Hospital | Taoyuan City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07569042